Quarterly ResultAug 6, 2026, 07:12 AM
Korro Bio Q2 Net Loss $(18.9M); Raises $85M in Private Placement
AI Summary
Korro Bio reported a net loss of $(18.9) million for Q2 2026, an improvement from $(25.8) million in Q2 2025, with no collaboration revenue for the quarter. The company significantly bolstered its liquidity by raising approximately $85 million in gross proceeds from a private placement and an additional $5 million from an at-the-market program. This capital infusion is expected to fund operations for at least 12 months, despite an accumulated deficit of $422.4 million and the pause of its collaboration with Novo Nordisk.
Key Highlights
- Q2 2026 net loss was $(18.9) million, compared to $(25.8) million in Q2 2025.
- Collaboration revenue was $0 for Q2 2026, down from $1.46 million in Q2 2025.
- Raised $85.0 million gross from a private placement in March 2026.
- Generated $5.02 million net from an at-the-market program.
- Cash, cash equivalents, and marketable securities totaled $137.9 million as of June 30, 2026.
- Net cash used in operating activities was $(33.1) million for H1 2026.
- Accumulated deficit reached $(422.4) million as of June 30, 2026.
- Novo Nordisk collaboration paused for 12 months as of November 2025.
Price Impact
More from KRRO